CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Sphenopalatine ganglion (SPG) nerve blocks for headache disorders — Coverage Criteria

This document governs coverage and medical necessity determinations for intranasal sphenopalatine ganglion blocks for headache indications (including migraine, cluster headache, PDPH, and acute severe headaches) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySphenopalatine ganglion (SPG) nerve blocks for headache disorders — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateAug 1, 2017

Next Review DateJan 1, 2026

Key ActionFile claims using unlisted nervous system procedure codes (e.g., 64999) when billing for the procedure and verify member benefits with the provider call center.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessaryCommercial stance

Not coveredMedicare Advantage stance

3FDA devices

MultipleRCTs & review

2024Latest guideline

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Clinical Position

Overall coverage stance

Coverage stance: SPG blocks are not covered or are considered not medically necessary for all headache indications (including migraines, non-migraine headaches, cluster headache, post‑dural puncture headache, and acute severe headaches treated in the ED) because the evidence is insufficient to determine effects on health outcomes.

Medicare Advantage: not covered; Commercial Products: not medically necessary.

Sphenopalatine ganglion (SPG) blocks are excluded / not medically necessary for all headache indications, including but not limited to migraines and non‑migraine headaches. This exclusion reflects the determination that the current evidence is insufficient to establish that SPG blocks improve net health outcomes for headache disorders.

For Commercial Products, SPG blocks are considered not medically necessary for all headache indications. Providers should expect that claims for SPG blocks for headache diagnoses may be denied under commercial benefit plans unless the member’s contract specifically provides coverage.

The body of evidence across multiple headache indications is limited and inconsistent. For severe acute headache treated in the emergency setting, a single randomized, double‑blind, placebo‑controlled trial showed no statistically significant benefit at 15 minutes and mixed results thereafter. For cluster headache the evidence is limited to small case series with variable approaches and uncertain generalizability. For post‑dural puncture headache (PDPH), a systematic review of randomized trials found short‑term pain improvement at 30 minutes, 1 hour, and 4 hours but not at many later time points; study heterogeneity, small sample sizes, and variable anesthetic regimens limit conclusions. Overall, the evidence is insufficient to determine that SPG blocks produce a meaningful improvement in net health outcomes for the listed headache indications.

Coverage under this medical policy is informational and subject to the member’s specific benefit documents. The member’s subscriber agreement, member certificate, or employer agreement will supersede the provisions of this policy; verify benefits and eligibility with the provider call center before providing services.

Coding and Billing Codes

Unlisted procedure codes (billing guidance)CPT

64999

Unlisted procedure, nervous system

Specific CPT code listed as not coveredCPTNot Covered

64505

Injection, anesthetic agent; sphenopalatine ganglion

Provider Actions, Prior Authorization & Billing Guidance

Note

Prior Authorization

Prior authorization is not applicable for this policy.

Denial Risk

Coverage Denial Risk

Sphenopalatine ganglion (SPG) blocks are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products for all headache indications, including but not limited to treatment of migraines and non-migraine headaches.

Medicare Advantage Plans: SPG blocks are not covered for all headache indications.
Commercial Products: SPG blocks are considered not medically necessary for all headache indications.

Clinical Background and Context

Background: Headache disorders (including tension‑type headache, migraine, cluster headache, and postdural puncture headache) are common neurologic conditions with diverse causes and management strategies. The sphenopalatine ganglion (SPG) has been targeted as a potential treatment site because sensory fibers associated with cranial autonomic symptoms and head pain converge there. SPG blocks deliver topical local anesthetic to the ganglion—most commonly via an intranasal approach using applicators or catheters—with the aim of transiently interrupting pain signaling.

Although some trials and a systematic review report short‑term pain relief for selected indications (for example, transient improvement in PDPH), the optimal technique, dose, frequency, and durability of benefit are unclear. Devices and delivery methods vary, and available studies include small randomized trials, case series, and heterogeneous protocols. Given these limitations, current evidence does not demonstrate a consistent, durable net health benefit for SPG blocks in treating headache disorders.

Definitions

inv-18: Definition — Sphenopalatine ganglion (SPG) block (topical intranasal application description)

DefinitionTopical application of local anesthetic to the nasal mucosa overlying the sphenopalatine ganglion using an intranasal catheter or applicator to target sensory fibers linked to headache pain.

Typical agentsLocal anesthetics such as lidocaine or bupivacaine delivered via syringe-attached intranasal catheter, cotton-tipped applicator, or proprietary catheter devices.

PurposeAimed at blocking sensory fibers of the SPG to reduce headache pain while preserving autonomic function.

Device availabilityThree catheter devices are commercially available in the U.S. for performing intranasal SPG blocks.

inv-19: Definition — Chronic migraine (diagnostic frequency criteria)

Frequency threshold

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySphenopalatine ganglion (SPG) nerve blocks for headache disorders — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateAug 1, 2017

Next Review DateJan 1, 2026

Key ActionFile claims using unlisted nervous system procedure codes (e.g., 64999) when billing for the procedure and verify member benefits with the provider call center.

SourceLink

On This Page

Billing Rule

Billing Guidance & Specific Non‑covered CPT

There is no specific CPT code for this procedure. Claims should be filed with an unlisted nervous system procedure code per policy guidance. The CPT code 64505 (Injection, anesthetic agent; sphenopalatine ganglion) is specifically listed as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

File claims using unlisted nervous system procedure code: 64999 Unlisted procedure, nervous system.
Do not use CPT 64505 — listed as not covered / not medically necessary.

Note

Benefit Variability

Benefits and eligibility vary by contract. Refer to the member's Benefit Booklet, Evidence of Coverage or Subscriber Agreement for specific coverage details. Contact the provider call center for member-specific benefit verification; the subscriber agreement or employer agreement supersedes this policy.

Documentation Required

Member Financial Responsibility if Service Not Covered

If a service is determined to be not medically necessary or is a non-covered benefit under the member's plan, providers may not charge the member for the service unless the member has been informed in advance and has agreed in writing to pay at their own expense. Refer to your participation agreement(s) for applicable provisions and contact the provider call center for benefit verification.

Provider must obtain written member agreement in advance to bill member for non‑covered services.
For member-specific benefits or questions, call the provider call center.

Migraine attacks on at least 15 days per month for more than 3 months.

Migraine-feature daysHeadache with features of migraine on at least 8 days per month.

Classification noteChronic migraine is a frequency-based subtype of migraine; may be categorized by presence or absence of aura.

inv-20: Definition — Postdural puncture headache (PDPH) clinical description

Clinical timingHeadache that occurs after dural puncture or with low cerebrospinal fluid volume from a dural leak.

Positional characteristicBilateral frontal or occipital headache that worsens with sitting or standing and is relieved when supine.

Associated symptomsMay include nausea, neck stiffness, low back pain, tinnitus, and visual disturbances.

Incidence noteReported incidence after lumbar puncture varies (approximately 10%–40%; may be as low as 2% with small-gauge non-cutting needles).

inv-21: Definition — SPG block (transnasal or endoscopic local anesthetic application)

Procedure descriptionTransnasal or endoscopic application of local anesthetic to the SPG via intranasal catheter, applicator, or endoscopic approach to reach the posterior nasal cavity overlying the ganglion.

Technique variationsOriginally performed with cotton-tipped applicators; current methods use catheter devices (including SpenoCath®, Allevio™, Tx360®) or endoscopic approaches.

Treatment intentUsed for acute abortive treatment in emergency settings and proposed for short- or long-term management of chronic headaches and cluster headache.

Unclear parametersOptimal number and frequency of treatments are not well established; RCTs have used courses such as twice weekly for 6 weeks (12 treatments).

inv-22: Definition — Epidural blood patch (treatment for PDPH)

DefinitionInjection of autologous blood into the epidural space as a treatment for post-dural puncture headache (PDPH).

PurposeAimed at sealing dural leaks and restoring normal cerebrospinal fluid pressure to relieve PDPH symptoms.

EvidenceRandomized and controlled trials have evaluated epidural blood patch efficacy for PDPH (multiple trials cited).